These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 28992296

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension.
    Supasyndh O, Sun N, Kario K, Hafeez K, Zhang J.
    Hypertens Res; 2017 May; 40(5):472-476. PubMed ID: 27853163
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Sacubitril/Valsartan in Chronic Type B Aortic Dissection Combined With Mild Hypertension.
    Wang X, Song F, Jiang L, Huang Z, Luo S, Li X, He X.
    Am J Hypertens; 2024 Jul 15; 37(8):612-620. PubMed ID: 38564196
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
    Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, Guo W.
    Hypertension; 2017 Mar 15; 69(3):411-420. PubMed ID: 28093466
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.
    Cheung DG, Aizenberg D, Gorbunov V, Hafeez K, Chen CW, Zhang J.
    J Clin Hypertens (Greenwich); 2018 Jan 15; 20(1):150-158. PubMed ID: 29338113
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.
    Ito S, Satoh M, Tamaki Y, Gotou H, Charney A, Okino N, Akahori M, Zhang J.
    Hypertens Res; 2015 Apr 15; 38(4):269-75. PubMed ID: 25693859
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antihypertensive effect of sacubitril/valsartan: a meta-analysis.
    De Vecchis R, Ariano C, Soreca S.
    Minerva Cardioangiol; 2019 Jun 15; 67(3):214-222. PubMed ID: 30895762
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S.
    Hypertension; 2011 Mar 15; 57(3):413-20. PubMed ID: 21282560
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.